Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study

Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study

Background: Long COVID has become a central public health concern. This study characterized the effectiveness of BNT162b2 BA.4/5 bivalent COVID-19 vaccine (bivalent) against long COVID symptoms. Methods: Symptomatic US adult outpatients testing positive for SARS-CoV-2 were recruited between 2 March...

Full description

Bibliographic Details
Main Authors:	Manuela Di Fusco, Xiaowu Sun, Kristen E. Allen, Alon Yehoshua, Alexandra Berk, Mary B. Alvarez, Thomas M. Porter, Jinma Ren, Laura Puzniak, Santiago M. C. Lopez, Joseph C. Cappelleri
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Vaccines
Subjects:	BNT162b2 bivalent BA.4/5 long COVID PASC COVID-19
Online Access:	https://www.mdpi.com/2076-393X/12/2/183

Similar Items

Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy
by: Manuela Di Fusco, et al.
Published: (2023-10-01)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
by: Hagit Kopel, et al.
Published: (2023-11-01)

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
by: Shanti Pather, et al.
Published: (2023-12-01)

Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron
by: Manuela Di Fusco, et al.
Published: (2023-07-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
by: Hagit Kopel, et al.
Published: (2024-09-01)

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
by: Juleen Gayed, et al.
Published: (2024-07-01)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022-06-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2022-12-01)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
by: Einat Shacham Shmueli, et al.
Published: (2022-08-01)

Aseptic meningitis after BNT-162b2 COVID-19 vaccination
by: Amanda CY. Chan, et al.
Published: (2022-02-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
by: Efrén Murillo-Zamora, et al.
Published: (2021-07-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
by: Lotus Leonie van den Hoogen, et al.
Published: (2022-09-01)

BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
by: Flavia Beccia, et al.
Published: (2023-02-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
by: Mazin Barry, et al.
Published: (2022-01-01)

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
by: Eric Yuk Fai Wan, et al.
Published: (2024-09-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
by: Itzchak Levy, et al.
Published: (2022-07-01)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024-02-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
by: Toh Leong Tan, et al.
Published: (2022-12-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
by: Rui Li, et al.
Published: (2022-06-01)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
by: Su Lan Yang, et al.
Published: (2022-12-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
by: Antti Hurme, et al.
Published: (2022-04-01)

Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
by: Keiji Hirai, et al.
Published: (2024-05-01)

Associations between symptom-based long COVID clusters and long-term quality of life, work and daily activities among individuals testing positive for SARS-CoV-2 at a national retail pharmacy
by: Manuela Di Fusco, et al.
Published: (2024-10-01)

Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden
by: Vibeke Manniche, et al.
Published: (2024-08-01)

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event
by: Nikolaos Syrigos, et al.
Published: (2022-05-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01)

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
by: Areti Tychala, et al.
Published: (2021-12-01)

Polyneuritis Cranialis Associated with BNT162b2 mRNA COVID-19 Vaccine in a Healthy Adolescent
by: Pimchanok Kulsirichawaroj, et al.
Published: (2022-01-01)

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
by: Joel M. Neutel, et al.
Published: (2025-02-01)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024-12-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
by: Marika Watanabe, et al.
Published: (2022-01-01)

Variety of Antibody Responses to BNT162b2 and BBIBP-CorV Vaccinations Against COVID-19 Infections in Baghdad and Fallujah, Iraq
by: Mohammed A. Hamad, et al.
Published: (2023-08-01)